Zanidatamab (zani), a HER2-targeted bispecific antibody, in combination with docetaxel as first-line (1L) therapy for patients (pts) with advanced HER2-positive breast cancer: Preliminary results from ...
Encouraging safety and preliminary efficacy analysis from the elacestrant and capivasertib Phase 1b regimen of the ELEVATE study will be ...
The Company confirms that it will release 2.5 year overall survival data from Phase 2b clinical trial OST-HER2 in the ...
Enhertu Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors ...
If you or a loved one has lung cancer, you may be looking into treatment options. A new medicine you might hear about is Hernexeos (zongertinib). More specifically, Hernexeos is FDA-approved to treat ...
New approvals for fam-trastuzumab deruxtecan-nxki establish a potential new standard of care in the neoadjuvant and adjuvant settings for patients with HER2-positive early breast cancer.
With AstraZeneca and Daiichi Sankyo’s practice-changing clinical data for Enhertu in a new breast cancer category called HER2-low, experts have raised the necessity of revolutionizing the HER2 ...
HER2-positive cancer cells produce HER2 protein that stimulates cell growth. Stage 4 HER2-positive esophageal cancer has a poor outlook, but some targeted therapy drugs may help people live longer.
Drugs designed to target HER2-postive breast cancer could also benefit some patients with bile duct cancer, according to results of a patient trial to be presented on Thursday at the 36th ...
Encouraging safety and preliminary efficacy analysis from the elacestrant and capivasertib Phase 1b regimen of the ELEVATE study will be presented. The efficacy data highlight how ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results